Document Detail


Vitamin C, gastritis, and gastric disease: a historical review and update.
MedLine Citation:
PMID:  22543844     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The discovery of Helicobacter pylori as the cause of gastritis and peptic ulcers ushered in the modern era of research into gastritis and into acid-peptic diseases and rekindled interest in the role of ascorbic acid in the pathophysiology and treatment of gastritis and peptic ulcer disease. Here, we review historic and modern studies on ascorbic acid and gastric diseases with an emphasis on H. pylori gastritis and its sequelae. The relationship of ascorbic acid and gastritis and peptic ulcer and its complications was extensively studied during the 1930s through the 1950s. Much of this extensive literature has been effectively "lost." Ascorbic acid deficiency was associated with all forms of gastritis (e.g., autoimmune, chemical, and infectious) due in varying degrees to insufficient intake, increased metabolic requirements, and destruction within the GI tract. Importantly, gastritis-associated abnormalities in gastric ascorbic acid metabolism are reversed by H. pylori-eradication and potentially worsened by proton pump inhibitor therapy. Diets rich in naturally occurring ascorbic acid are associated with protection of the gastric corpus from atrophy and a reduction in the incidence of gastric cancer possibly through the ability of ascorbic acid to reduce oxidative damage to the gastric mucosa by scavenging carcinogenic N-nitroso compounds and free radicals and attenuating the H. pylori-induced inflammatory cascade. Ascorbic acid supplementation was possibly associated with a decreased incidence of bleeding from peptic ulcer disease. Pharmacologic doses of ascorbic acid also may improve the effectiveness of H. pylori-eradication therapy. Occasionally, looking back can help plot the way forward.
Authors:
Anupam Aditi; David Y Graham
Related Documents :
3436854 - The antibacterial activity of alamethicins and zervamicins.
3026284 - Effect of defaunation and refaunation of the rumen on rumen fermentation and n-flow in ...
17488024 - Volatile organic sulfur-containing constituents in poncirus trifoliata (l.) raf. (rutac...
16417294 - Effect of high-pressure treatment and a bacteriocin-producing lactic culture on the odo...
7356694 - Gastric acid secretion is abnormally sensitive to endogenous gastrin released after pep...
21726384 - Arabidopsis thaliana cdd1 mutant uncouples the constitutive activation of salicylic aci...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review     Date:  2012-04-28
Journal Detail:
Title:  Digestive diseases and sciences     Volume:  57     ISSN:  1573-2568     ISO Abbreviation:  Dig. Dis. Sci.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-09-26     Completed Date:  2012-12-28     Revised Date:  2014-01-10    
Medline Journal Info:
Nlm Unique ID:  7902782     Medline TA:  Dig Dis Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2504-15     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Ascorbic Acid / blood,  metabolism,  pharmacology*
Ascorbic Acid Deficiency / complications*
Helicobacter Infections / complications*,  drug therapy,  microbiology
Helicobacter pylori
Humans
Stomach Diseases / etiology*
Grant Support
ID/Acronym/Agency:
CA116845/CA/NCI NIH HHS; DK067366/DK/NIDDK NIH HHS; DK56338/DK/NIDDK NIH HHS; M01 RR000188/RR/NCRR NIH HHS; P30 DK056338/DK/NIDDK NIH HHS; R01 CA116845/CA/NCI NIH HHS; R01 DK063092/DK/NIDDK NIH HHS; R21 DK067366/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
PQ6CK8PD0R/Ascorbic Acid
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A new type of silica-coated Gd(2)(CO(3))(3):Tb nanoparticle as a bifunctional agent for magnetic res...
Next Document:  Long-Term Risk of Cholangitis in Patients with Metal Stents for Malignant Biliary Obstruction.